<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003419</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066438</org_study_id>
    <secondary_id>ITA-GICAT-POS2</secondary_id>
    <secondary_id>EU-97019</secondary_id>
    <nct_id>NCT00003419</nct_id>
  </id_info>
  <brief_title>Antiviral Therapy in Treating Patients With Slowly Progressing HIV-Related Kaposi's Sarcoma</brief_title>
  <official_title>Treatment of HIV-Related Kaposi's Sarcoma and Stage I-III Slow-Proliferative Disease With Highly Active Antiretroviral Therapy (HAART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro di Riferimento Oncologico - Aviano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: HIV virus is found in the lesions of most patients with Kaposi's sarcoma, and may&#xD;
      have a role in causing Kaposi's sarcoma. Antiviral therapy acts against the HIV virus and may&#xD;
      be an effective treatment for Kaposi's sarcoma.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well antiviral therapy works in treating&#xD;
      patients with slowly progressing HIV-related Kaposi's sarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of highly active antiretroviral therapy (HAART) in treating&#xD;
           patients with HIV-related stage I-III nonaggressive epidemic Kaposi's sarcoma.&#xD;
&#xD;
      OUTLINE: Patients receive therapy consisting of nucleoside analogues (RTI) and protease&#xD;
      inhibitors (PI). Patients may receive either 2 RTIs or 2 RTIs plus 2 PIs. Treatment continues&#xD;
      for 12 weeks, then progression is assessed.&#xD;
&#xD;
      Patients with stable or regressing Kaposi's sarcoma (KS) with a viral load of greater than&#xD;
      500 copies of RNA/mL may continue with the therapy (if the viral load has decreased by&#xD;
      greater than 2 logs) or may modify therapy (if the viral load has decreased less than 2&#xD;
      logs). Patients with progressive disease may begin chemotherapy but continue to receive the&#xD;
      antiretroviral therapy. Treatment continues for at least 48 weeks.&#xD;
&#xD;
      Patients are followed every 8 weeks until week 48.&#xD;
&#xD;
      PROJECTED ACCRUAL: This study will accrue a total of 14-25 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 1998</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
  </primary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antiviral therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Stage I-III (NYU) Kaposi's sarcoma that is slowly progressive&#xD;
&#xD;
               -  Stable disease without progression in diameter of tumor or in number of lesions&#xD;
                  (less than 50% increase in 3 months)&#xD;
&#xD;
               -  No progressive disease during or after treatment for Kaposi's sarcoma&#xD;
&#xD;
          -  Level of viral load detectable independently from CD4+ cells&#xD;
&#xD;
          -  No other active AIDS pathologies&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-3&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 1500/mm3&#xD;
&#xD;
          -  Hemoglobin greater than 8 mg/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.5 times normal&#xD;
&#xD;
          -  AST and ALT less than 5 times normal&#xD;
&#xD;
          -  Alkaline phosphatase less than 2.5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.5 times normal&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior malignancy except carcinoma in situ of the cervix or nonmelanomatous skin&#xD;
             cancer&#xD;
&#xD;
          -  No active cytomegalovirus, herpes simplex 1 or 2, or herpes zoster infection requiring&#xD;
             treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior antiretroviral therapy OR&#xD;
&#xD;
          -  No prior highly active antiretroviral therapy (HAART)&#xD;
&#xD;
          -  No concurrent acyclovir, ganciclovir, foscarnet, or cidofovir&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Umberto Tirelli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centro di Riferimento Oncologico - Aviano</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Aviano</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2001</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>AIDS-related Kaposi sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

